Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible lung disease. Studies have shown that epithelial-mesenchymal transition (EMT) plays an important role in the development of IPF. The NLRP3 inflammasome is reported to be activated and play an important role in many respiratory diseases. However, whether the NLRP3 inflammasome is activated in alveolar epithelial cells as well as the regulatory role of NLRP3 in EMT have not been reported. In this study, we transfected NLRP3 siRNA into A549 and RLE-6TN cells and treated them with bleomycin (BLM) for 24 h. Then, we detected the expression of NLRP3 inflammasome-related proteins, EMT-related proteins and transforming growth factor-β1 (TGF-β1) via western blotting, immunofluorescence and real-time quantitative PCR. The mRNA and protein level of NLRP3, ASC and caspase-1 increased after treatment with BLM. The IL-1β levels were significantly decreased after inhibition of NLRP3 and caspase-1. E-cadherin expression increased and α-SMA was reduced in the BLM group when inhibited by NLRP3. The level of TGF-β1 was reduced after NLRP3 silencing. These results indicated that the NLRP3 inflammasome was activated in alveolar epithelial cells and that NLRP3 may regulate EMT through TGF-β1. These results may extend our understanding of the mechanism of pulmonary fibrosis and provide a new therapeutic target for pulmonary fibrosis.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by the aberrant deposition of extracellular matrix leading to extensive lung remodeling [1] . IPF also belongs to a group of interstitial lung diseases that are characterized by various patterns of inflammation and fibrosis [2] . The prevalence and incidence of IPF appears to be increasing over the last decades, and the median survival time for patients is approximately 2-3 years after confirmed diagnosis [3] . Two antifibrotics, pirfenidone and nintedanib, have already been approved to treat IPF in the United States and Europe [4, 5] . However, the mechanism of pulmonary fibrosis still requires further study.
Type II alveolar epithelial cells are thought to function as stem cells in the lungs. Some studies have shown that alveolar epithelial cells are able to acquire a mesenchymal phenotype via the epithelial-mesenchymal transition (EMT) in the repair process after lung injury, and EMT is considered to be one of three sources for activated fibroblasts in pulmonary fibrosis [6] [7] [8] . In the recent years, many studies have focused on the function of EMT in pulmonary fibrosis [9] . Our previous work also showed that EMT participates in the development of paraquat-induced pulmonary fibrosis [10, 11] .
The inflammasome is a protein complex composed of platform proteins, adaptor proteins and effector proteins, which can be activated by pathogenic microorganisms, dead cells or irritants [12] . Inflammasome activation promotes the maturation of caspase-1, which further promotes increased interleukin-1β (IL-1β) and interleukin-18 (IL-18) release to participate in immuno-inflammatory responses [13] . Recent work has revealed that the levels of NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) and caspase-1 were significantly increased in the untreated bronchoalveolar lavage fluid macrophages of IPF patients, as were IL-1β levels [14] . NLRP3 inflammasome activation is also observed in pulmonary fibrosis models induced by asbestos, silica and bleomycin, and pulmonary fibrosis is alleviated by the inhibition of NALP3 inflammasome activation [15] .
Some studies have shown that NLRP3 regulates EMT via transforming growth factor-β1 (TGF-β1) signaling in renal and liver fibrosis [16, 17] . However, whether the NLRP3 inflammasome is also activated in type II alveolar epithelial cells and the role of NLRP3 in modulating EMT in pulmonary fibrosis has not been reported.
Thus, the aim of this study was to investigate the potential role of NLRP3 in regulating EMT in BLM-induced pulmonary fibrosis. This work may further illuminate the mechanism of pulmonary fibrosis and provide a new therapeutic target for pulmonary fibrosis.
Materials and methods

Materials
Anti-NLRP3, anti-ASC and anti-caspase-1 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-α-SMA (α-smooth muscle actin), anti-E-cadherin and anti-TGF-β1 were obtained from Abcam (Cambridge, MA, USA). Anti-Tubulin, horseradish peroxidase-conjugated secondary antibodies, RIPA protein lysis buffer, PMSF, a BCA protein concentration assay kit, an SDS-PAGE gel preparation kit, Alexa Fluor 647-labeled goat anti-mouse IgG, Alexa Fluor 488-labeled goat anti-mouse IgG, DAPI, Immunol Staining Blocking Buffer and Immunol Staining Fix Solution were purchased from Beyotime (Shanghai, China).
Cell culture
A549 and RLE-6TN cells were purchased from the American Type Culture Collection (Rockville, MD, USA). A549 cells were grown in DMEM (Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and 1% antibiotics (100 U/ml penicillin, 0.1 mg/ml streptomycin). RLE-6TN cells were cultured in DMEM/F-12 (HyClone Logan, City, UT, USA) with 10% fetal bovine serum and 1% antibiotics. All cell lines were cultured at 37°C in a humidified incubator with 5% carbon dioxide. 
Real-time quantitative PCR
Cells were washed three times with PBS after treatment with BLM. Total RNA was extracted from cells using the TRIzol (Invitrogen, Grand Island, NY, USA) reagent according to the manufacturer's instructions. Total RNA concentrations were determined using an ultraviolet spectrophotometer. Reverse transcription was performed using a Prime Script™ RT Master Mix Kit (TaKaRa, Dalian, Liaoning, China) according to the manufacturer's instructions. Real-time quantitative PCR was performed using a SYBR® Premix Ex Taq™ Kit (TaKaRa, Dalian, Liaoning, China) and an ABI ViiATM 7 System. The specific primers for NLRP3, ASC, caspase-1 and β-actin were generated by BioTNT (Shanghai, China) and are shown in Table 1 . For each experiment, at least three parallel measurements were carried out, and β-actin served as a loading control.
Transient transfection
NLRP3 siRNA and negative-control sequences were purchased from GenePharma (Shanghai, China). NLRP3 siRNA and scrambledcontrol sequences were transfected into both cell lines using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) following the manufacturer's instructions. After 48 h, the cells were collected and subjected to the following detection methods.
Western blotting
Cells were washed three times with PBS after treatment with BLM. Total protein from the cells in each group was harvested using RIPA buffer. Protein concentrations were determined with a BCA protein assay kit. Total protein samples were separated via 10% SDS-PAGE and transferred to PVDF membranes (Bio-Rad, Richmond, CA, USA). After blocking with 5% non-fat milk in Tris-buffered saline with Tween 20 (TBST), the membranes were incubated with the relevant primary antibody. Tubulin was used as a loading control. The secondary antibodies, horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG and goat anti-mouse IgG, were incubated with the membranes for 60 min at room temperature. After the membranes were washed in TBST, the proteins were visualized with the ECL (Thermo Fisher Scientific, Waltham, MA, USA) detection system.
Immunofluorescence
A549 cells were seeded in confocal dishes and transfected with NLRP3 siRNA as described above. Then, the cells were treated with BLM for 24 h. The cells were washed three times with PBS, fixed with Immunol Staining Fix Solution for 10 min, and blocked with Immunol Staining Blocking Buffer for 1 h at room temperature. The cells were incubated with primary antibodies (E-cadherin, 1:50; α-SMA, 1:50) overnight at 4°C, after which the cells were washed three times with TBST and incubated with Alexa Fluor 488-labeled goat anti-mouse IgG (E-cadherin) or Alexa Fluor 647-labeled goat anti-mouse IgG (a-SMA) secondary antibodies for 1.5 h in the dark at room temperature. The cells were counter-stained with DAPI to visualize the nuclei. Fluorescence images were acquired on a laser confocal microscope (Leica TCS SP8, Leica, Wetzlar, Germany).
Enzyme-linked immunosorbent assay (ELISA)
The human IL-1β ELISA Kit was purchased from Anogen (Mississauga, Ontario, Canada), the human IL-18 ELISA Kit was purchased from R & D Systems, Inc. (Minneapolis, MN, USA), the rat IL-1β ELISA Kit was purchased from BioTNT (Shanghai, China), and the rat IL-18 ELISA Kit was obtained from Boster (Wuhan, China). IL-1β and IL-18 levels in the cells culture supernatants were detected according to the manufacturer's protocol for the corresponding kit. All experiments were performed in triplicate.
Statistical analysis
All statistical analyses were performed with SPSS (version 16.0, SPSS). All experiments were repeated at least three times. Data are expressed as the mean ± standard deviation. Comparisons between two groups were performed using t-tests. Statistical significance was set at P < 0.05.
Results
EMT participates in the process of BLM-induced pulmonary fibrosis
We first confirmed the median lethal dose of BLM in A549 and R. Tian et al.
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RLE-6TN cells using the CCK-8 assay. The result indicated that the appropriate concentrations of BLM in treated cells at 24 h were 120 μM for A549 cells (Fig. 1A) and 40 μM for RLE-6TN cells (Fig. 1B) . Then, we detected the expression of EMT-related markers by western blotting after the two cell lines were treated with BLM. We found that E-cadherin levels decreased significantly and that α-SMA expression markedly increased in A549 cells (Fig. 1C) . Similar results were obtained in RLE-6TN cells (Fig. 1D ). These data confirmed that EMT may play an important role in the development of BLM-induced pulmonary fibrosis.
NLRP3 and inflammasome gene expression increased in alveolar epithelial cells
Next, we detected the expression of NLRP3 inflammasome genes using real-time quantitative RT-PCR and western blotting. NLRP3, ASC (apoptosis-associated speck-like protein containing a CARD) and caspase-1 mRNA levels were significantly increased in A549 (Fig. 2A) and RLE-6TN (Fig. 2B ) cells after BLM treatment. We also found that NLRP3, ASC and caspase-1 protein levels were markedly increased in A549 cells in the BLM group (Fig. 2C) , with similar results obtained in RLE-6TN cells (Fig. 2D) . The above data indicated that the NLRP3 inflammasome was activated in type II alveolar epithelial cells and may participate in the development of BLM-induced pulmonary fibrosis.
IL-1β and IL-18 expression in the medium after BLM treatment
Studies have shown that increased caspase-1 can promote IL-1β and IL-18 levels, and many inflammatory cytokines have been confirmed to play an important role in the mechanism of pulmonary fibrosis. We therefore detected the expression of IL-1β and IL-18 in conditioned medium from alveolar epithelial cells by ELISA. The results showed that IL-1β levels were increased in both A549 (Fig. 3A) and RLE-6TN (Fig. 3B) cells. However, IL-18 levels were not significantly altered in either cell line. These data showed that IL-1β may also have a role in the progression of pulmonary fibrosis.
The role of NLRP3 in regulating BLM-induced EMT in vitro
To investigate the role of NLRP3 in BLM-induced EMT, we silenced NLRP3 expression by transiently transfecting both cell lines with NLRP3 siRNAs. Real-time quantitative RT-PCR revealed that NLRP3 mRNA levels were significantly reduced in A549 and RLE-6TN cells (Fig. 4A) . We also found that NLRP3 proteins levels were reduced in A549 cells. In the BLM group, E-cadherin expression increased and α-SMA levels were reduced after NLRP3 silencing (Fig. 4B) , and similar results were obtained in RLE-6TN cells (Fig. 4C) . Under phase contrast microscopy, both cell lines appeared to undergo morphological changes from a polygonal or cobblestone morphology to fusiform in the BLM group. However, this morphological change was alleviated after silencing the expression of NLRP3 (Fig. 4D) . As shown by immunofluores- Primer sequences of NLRP3, ASC, Caspase-1 and β-actin which used in real-time quantitative PCR. β-actin served as a loading control. Abbreviation: NLRP3 = NOD-like receptor family, pyrin domain-containing protein 3; ASC = apoptosis-associated speck-like protein containing a CARD. 
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cence, E-cadherin expression increased significantly and α-SMA expression was markedly reduced in NLRP3-silenced A549 cells (Fig. 4E) . Thus, we speculated that NLRP3 may play an important role in modulating BLM-induced EMT.
IL-1β expression was reduced after NLRP3 and caspase-1 inhibition
Next, we detected the expression of IL-1β after inhibiting NLRP3 and caspase-1. The results showed that caspase-1 mRNA and protein levels were significantly reduced in A549 and RLE-6TN cells transfected with caspase-1 siRNA (Fig. 5A and B) . The levels of IL-1β in the supernatants of both cell lines were significantly decreased after NLRP3 and caspase-1 inhibition (Fig. 5C and D) . These results indicated that BLM-induced IL-1β expression may be modulated by the NLRP3 inflammasome in the alveolar epithelial cells.
NLRP3 may modulate BLM-induced EMT via TGF-β1
To further investigate the potential mechanism by which NLRP3 regulates BLM-induced EMT, we detected the expression of TGF-β1 by western blotting after silencing the expression of NLRP3 in vitro. TGF-β1 is known to be a key factor in the development of EMT and pulmonary fibrosis [18, 19] . We found that TGF-β1 protein levels were significantly reduced in A549 (Fig. 6A) and RLE-6TN cells (Fig. 6B) when NLRP3 was silenced. These results suggested that NLRP3 may regulate BLM-induced EMT may through the TGF-β1 signaling pathway.
Discussion
IPF is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause. IPF is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis [20] . Presently, methods for treating pulmonary fibrosis are still limited, and thus, studying its mechanism is of great importance.
Type II alveolar epithelial cells (AEC-II) are considered to function as adult stem cells in the lungs. Under normal physiological conditions, the proliferation, differentiation, apoptosis and secretory functions of AEC-IIs maintain the normal lung function. AEC-IIs also participate in repair processes in the lungs by proliferating and differentiating to replace injured cells during lung injury [21] . Studies have shown that AEC-IIs can acquire mesenchymal cell phenotypes via the epithelialmesenchymal transition, which plays an important role in the mechanism of pulmonary fibrosis [9] . During this process, AEC-IIs lose the expression of epithelial cell-related markers (e.g., E-cadherin, ZO-1) and gain the expression of mesenchymal cell-related markers (e.g., α-SMA, vimentin) [22, 23] . These changes can promote the deposition of extracellular matrix and the development of pulmonary fibrosis. Our study showed that the level of E-cadherin was reduced and the expression of α-SMA was increased in both A549 and RLE-6TN cells after BLM treatment. These data indicated that EMT plays an important role in BLM-induced pulmonary fibrosis.
The inflammasome was initially thought to exclusively activate inflammatory responses. However, studies have shown that inflamma- some activation is linked to the development of cancer, as well as to autoimmune, metabolic and neurodegenerative diseases, and may be a potential therapeutic target [24, 25] . NLRP3 and caspase-1 levels were reported to increase in the untreated bronchoalveolar lavage fluid macrophages of IPF patients, as did IL-1β levels [14] . Inhibiting the activation of the NLRP3 inflammasome attenuates pulmonary inflammation and fibrosis [15] . However, the relationship between the NLRP3 inflammasome and EMT has not been studied in pulmonary fibrosis. In renal and liver fibrosis, studies have shown that the NLRP3 inflammasome can promote EMT via the TGF-β1/Smad signaling pathways [16, 17] . In our study, we found that the NLRP3 inflammasome was activated in AEC-IIs in BLM-induced pulmonary fibrosis. IL-1β levels were markedly increased; however, IL-18 expression was not significantly altered, and there may have other mechanisms of regulat- ing IL-18. Some studies have reported that NLRP3 inflammasome activated and IL-18 increased in the lung macrophages after BLM treatment [26] . At the condition of LPS + ATP or hyperosmotic stress, IL-18 expression increased in the A549 cells [27, 28] . However, it also reported that IL-18 could alleviate BLM-induced lung injury [29] . Thus, the role of IL-18 in alveolar epithelial cells still did not clear and need to be studied further. The degree of EMT was also alleviated when we silenced the expression of NLRP3 in alveolar epithelial cells. These results revealed that NLRP3 may participate in the process of BLMinduced EMT.
To investigate the potential pathway by which NLRP3 regulates BLM-induced EMT, we detected the expression of TGF-β1 after silencing NLRP3 in both A549 and RLE-6TN cell lines. TGF-β1 is thought to be a key factor in the development of pulmonary fibrosis [25, 30] , and TGF-β1 also plays an important regulatory role in EMT [31] . TGF-β1 protein levels were markedly reduced after we silenced the expression of NLRP3. NLRP3 may regulate the expression of TGF-β1 by influencing the level of IL-1β, which can elevate TGF-β1 in pulmonary fibrosis [32] . The above data indicated that NLRP3 may regulate EMT through the TGF-β1 signaling pathway in BLM-induced pulmonary fibrosis.
In conclusion, we found that the NLRP3 inflammasome was activated in type II alveolar epithelial cells and that NLRP3 may modulate EMT through the TGF-β1 signaling pathway. This study may extend our understanding for the mechanism of pulmonary fibrosis and provide a new therapeutic target for pulmonary fibrosis.
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